Cell/Gene Tx channel feed

Bay­er takes next step in cell ther­a­py, open­ing new $250M fa­cil­i­ty in Berke­ley

Last year
Manufacturing

Ex­clu­sive: Cel­lares ex­pands deal with Bris­tol My­ers on CAR-T as­set, eyes man­u­fac­tur­ing ex­pan­sion

Last year
Manufacturing

At­se­na pri­or­i­tizes reti­nal gene ther­a­py pipeline, trims staff as ex­ist­ing in­vestors re­fu­el the biotech 

Last year
People

UniQure halves re­search, lays off 20% while CSO de­parts in ma­jor re­vamp

Last year
People
R&D

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics sells to Ky­owa Kirin for $387M cash as lead pro­gram awaits 2024 FDA ver­dict

Last year
Deals

GLP-1 gene ther­a­py trig­gers 25% weight loss in obese mice, clin­i­cal tri­als planned for next year

Last year
R&D

The End­points Slack in­ter­view: Celli­no CEO Nabi­ha Sak­layen on cell ther­a­py's fu­ture, Elon Musk and time trav­el

Last year
People
Startups

Ad­comm rec­om­mends FDA re­ject Brain­Stor­m's ALS drug af­ter com­pa­ny filed over protest

Last year
FDA+

Ex­clu­sive: CellFE rais­es $22M Se­ries A to ad­vance a new cell ther­a­py man­u­fac­tur­ing idea

Last year
Financing
Manufacturing

Ab­b­Vie drops Cari­bou part­ner­ship on gene-edit­ed CAR-T ther­a­py

Last year
R&D

FDA picks apart Brain­Stor­m's po­ten­tial ALS treat­ment ahead of Wednes­day ad­comm

Last year
FDA+

Dana-Far­ber, Brigham breakup could lead to a rip­ple ef­fect for CGT clin­i­cal tri­als for can­cer

Last year
In Focus

Q&A: No­vo Nordisk Foun­da­tion’s Celler­a­tor CEO Thomas Carlsen digs in­to $135.4M Dan­ish cell ther­a­py fa­cil­i­ty

Last year
Manufacturing

FDA wants to know: What's hold­ing up the de­vel­op­ment of in­di­vid­u­al­ized cell and gene ther­a­pies?

Last year
FDA+

Taysha stops de­vel­op­ing a gene ther­a­py amid de­bate over FDA’s stance on ul­tra-rare tri­als

Last year
R&D

RNA edit­ing start­up launch­es with $30M based on Stan­ford and Uni­ver­si­ty of Tübin­gen re­search

Last year
Financing
Startups

Plat­form des­ig­na­tions: FDA's new cell and gene ther­a­py su­per of­fice di­rec­tor sees po­ten­tial

Last year
FDA+

Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

Last year
Financing
Startups

Not 'TIL' 2024: Io­vance’s li­fileu­cel faces yet an­oth­er ap­proval de­lay, this time due to FDA re­source con­straints

Last year
FDA+

Q&A: Lon­za CGT pres­i­dent Daniel Pal­mac­ci talks man­u­fac­tur­ing amid low­er sales out­look

Last year
Manufacturing

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

Last year
Startups
R&D

Roy­al­ty Phar­ma ex­ecs shed light on strat­e­gy be­hind their first gene ther­a­py deal

Last year
Deals

Up­dat­ed: 2sev­en­ty lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO

Last year
People

Up­dat­ed: No­var­tis dis­con­tin­ues lead Gy­ro­scope gene ther­a­py af­ter $800M+ buy­out

Last year
R&D
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times